“Starting next year, American drug prices will come down fast and furious and will soon be the lowest in the developed world, ...

The U.S. Food and Drug Administration said on Friday it has granted national priority vouchers to Merck's cholesterol pill ...

Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced the presentation of compelling new findings from the REPATHA-CE study of ...

DURHAM, N.C., November 25, 2025--(BUSINESS WIRE)--Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced the presentation of ...

Patients receiving Repatha achieved a median LDL cholesterol level of 45 mg/dL compared to 109 mg/dL in the placebo group. "Repatha has once again demonstrated its ability to protect patients from the ...

THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. NEW ORLEANS — A cholesterol-lowering injection ...

Amgen announced the launch of AmgenNow, a new direct-to-patient programme starting with Repatha (evolocumab). This follows landmark results demonstrating Repatha significantly reduced the risk of ...

AmgenNow, a direct-to-patient program, launches with Repatha, following positive Phase III Vesalius-CV trial results showing reduced cardiovascular events. Starting October 6, 2025, AmgenNow will be ...

Amgen (NASDAQ:AMGN) said on Monday that it has launched its cholesterol medication, Repatha, directly to consumers in the U.S. at a reduced cash price. This move comes as part of a broader response ...